Diabetes Care, Vol 16, Issue 1 21-31, Copyright © 1993 by American Diabetes Association

ARTICLES

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial

RR Henry, B Gumbiner, T Ditzler, P Wallace, R Lyon and HS Glauber
Department of Medicine, University of California, San Diego.

OBJECTIVE--To determine whether tight glycemic control can be obtained using intensive conventional split-dose insulin therapy in the outpatient management of type II diabetes without development of unacceptable side effects. RESEARCH DESIGN AND METHODS--Fourteen type II diabetic subjects were treated with an intensive program of conventional insulin (subcutaneous NPH and regular insulin before breakfast and supper) for 6 mo. Insulin dose adjustments were based on an algorithm built on frequent CPG measurements (4-6 times/day). Patients were monitored biweekly as outpatients and admitted 1 day/mo for metabolic evaluation. RESULTS--Glycemic control was achieved by 1 mo (mean plasma glucose fell from 17.5 +/- 0.9 to 7.7 +/- 0.7 mM, P < 0.001) and remained in this range thereafter. Hypoglycemic events at 1 mo were infrequent (mean +/- SE events per patient per month: 4.1 +/- 0.3) and mild in nature, and progressively decreased to 1.3 +/- 0.5 events/mo by 6 mo. After treatment, basal HGO fell 44% from 628 +/- 44 to 350 +/- 17 mumol.m-2.min-1 (P < 0.001), and maximal rates of glucose disposal measured by hyperinsulinemic euglycemic clamp (1800 pmol.m-2.min-1) improved from 1418 +2- 156 to 1657 +/- 128 mumol.m-2.min-1 (P < 0.05). The total dose of exogenous insulin required was 86 +/- 13 U at 1 mo and 100 +/- 24 U at 6 mo. During treatment, mean serum insulin levels increased from 308 +/- 80 to 510 +/- 102 pM (P < 0.05), while body weight increased from 93.5 +/- 5.8 to 102.2 +/- 6.8 kg (P < 0.001). Both pre- and posttreatment glucose disposal rates correlated with the total exogenous insulin dose required to achieve glycemic control (r = -0.75 and -0.78, both P < 0.005). Weight gain was inversely related to the pretreatment glucose disposal rate (r = -0.53, P < 0.05) and directly correlated with both mean day-long serum insulin level (r = 0.67, P < 0.01) and total exogenous insulin dose (r = 0.62, P < 0.02). CONCLUSIONS--Intensive CIT, when combined with CBG measurements, can be used to rapidly improve glycemic control in type II diabetes without development of unacceptable hypoglycemia. This degree of metabolic improvement, however, requires large doses of exogenous insulin to overcome peripheral insulin resistance and results in greater hyperinsulinemia with progressive weight gain.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Ryan, M. B. E. Livingstone, P.-H. Ducluzeau, A. Salle, M. Genaitay, and P. Ritz Is a Failure to Recognize an Increase in Food Intake a Key to Understanding Insulin-Induced Weight Gain? Diabetes Care, March 1, 2008; 31(3): 448 - 450. [Abstract] [Full Text] [PDF]

				M. Massi-Benedetti and M. Orsini-Federici Treatment of Type 2 Diabetes With Combined Therapy: What are the pros and cons? Diabetes Care, February 1, 2008; 31(Supplement_2): S131 - S135. [Abstract] [Full Text] [PDF]

				E. Standl and O. Schnell Insulin as a First-Line Therapy in Type 2 Diabetes: Should the use of sulfonylureas be halted? Diabetes Care, February 1, 2008; 31(Supplement_2): S136 - S139. [Full Text] [PDF]

				M. Riddle, J. Frias, B. Zhang, H. Maier, C. Brown, K. Lutz, and O. Kolterman Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin Diabetes Care, November 1, 2007; 30(11): 2794 - 2799. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Exploring Treatment Strategies for Type 2 Diabetes Diabetes Care, October 1, 2007; 30(10): 2737 - 2745. [Full Text] [PDF]

				L. Juurinen, M. Tiikkainen, A.-M. Hakkinen, A. Hakkarainen, and H. Yki-Jarvinen Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E829 - E835. [Abstract] [Full Text] [PDF]

				I. B. Hirsch, R. M. Bergenstal, C. G. Parkin, E. Wright Jr., and J. B. Buse A Real-World Approach to Insulin Therapy in Primary Care Practice Clin. Diabetes, April 1, 2005; 23(2): 78 - 86. [Full Text] [PDF]

				M. B. Davidson Starting Insulin Therapy in Type 2 Diabetic Patients: Does it really matter how? Diabetes Care, February 1, 2005; 28(2): 494 - 495. [Full Text] [PDF]

				P. A. Hollander, L. Blonde, R. Rowe, A. E. Mehta, J. L. Milburn, K. S. Hershon, J.-L. Chiasson, and S. R. Levin Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 2 Diabetes: Results of a 6-month, randomized, comparative trial Diabetes Care, October 1, 2004; 27(10): 2356 - 2362. [Abstract] [Full Text] [PDF]

				K. B. Campbell and S. S. Braithwaite Hospital Management of Hyperglycemia Clin. Diabetes, April 1, 2004; 22(2): 81 - 88. [Full Text] [PDF]

				S. M. Willi, K. Martin, F. M. Datko, and B. P. Brant Treatment of Type 2 Diabetes in Childhood Using a Very-Low-Calorie Diet Diabetes Care, February 1, 2004; 27(2): 348 - 353. [Abstract] [Full Text] [PDF]

				S. A. Westphal and P. J. Palumbo Insulin and Oral Hypoglycemic Agents Should Not Be Used in Combination in the Treatment of Type 2 Diabetes Arch Intern Med, August 11, 2003; 163(15): 1783 - 1785. [Full Text] [PDF]

				D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]

				D. E. DeWitt and D. C. Dugdale Using New Insulin Strategies in the Outpatient Treatment of Diabetes: Clinical Applications JAMA, May 7, 2003; 289(17): 2265 - 2269. [Abstract] [Full Text] [PDF]

				C. D. Miller, C. S. Barnes, L. S. Phillips, D. C. Ziemer, D. L. Gallina, C. B. Cook, S. D. Maryman, and I. M. El-Kebbi Rapid A1c Availability Improves Clinical Decision-Making in an Urban Primary Care Clinic Diabetes Care, April 1, 2003; 26(4): 1158 - 1163. [Abstract] [Full Text] [PDF]

				P. A. Hollander, P. Levy, M. S. Fineman, D. G. Maggs, L. Z. Shen, S. A. Strobel, C. Weyer, and O. G. Kolterman Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-year randomized controlled trial Diabetes Care, March 1, 2003; 26(3): 784 - 790. [Abstract] [Full Text] [PDF]

				M. Kipnes, P. Dandona, D. Tripathy, J. G. Still, and G. Kosutic Control of Postprandial Plasma Glucose by an Oral Insulin Product (HIM2) in Patients With Type 2 Diabetes Diabetes Care, February 1, 2003; 26(2): 421 - 426. [Abstract] [Full Text] [PDF]

				I. M. El-Kebbi, C. B. Cook, D. C. Ziemer, C. D. Miller, D. L. Gallina, and L. S. Phillips Association of Younger Age With Poor Glycemic Control and Obesity in Urban African Americans With Type 2 Diabetes Arch Intern Med, January 13, 2003; 163(1): 69 - 75. [Abstract] [Full Text] [PDF]

				J. R. White Jr., S. N. Davis, R. Cooppan, M. B. Davidson, K. Mulcahy, G. A. Manko, and D. Nelinson Clarifying the Role of Insulin in Type 2 Diabetes Management Clin. Diabetes, January 1, 2003; 21(1): 14 - 21. [Abstract] [Full Text] [PDF]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]

				R. C. Turner, C. A. Cull, V. Frighi, R. R. Holman, and for the UK Prospective Diabetes Study Group Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) JAMA, June 2, 1999; 281(21): 2005 - 2012. [Abstract] [Full Text] [PDF]

				S. D. Wise, M. F. Nielsen, P. E. Cryer, and R. A. Rizza Overnight Normalization of Glucose Concentrations Improves Hepatic But Not Extrahepatic Insulin Action in Subjects with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2461 - 2469. [Abstract] [Full Text]

				M. C. Riddle, D. M. Karl, J. M. Poothullil, M. J. Lenhard, I. B. Hirsch, T. C. Evans, B. Gaster, P. V. M. Cromme, J. C. Shipp, L. Jovanovic, et al. Insulin Treatment for Type 2 Diabetes JAMA, May 20, 1998; 279(19): 1523 - 1526. [Full Text] [PDF]

				S. Schwartz, P. Raskin, V. Fonseca, J. F. Graveline, and The Troglitazone and Exogenous Insulin Study Group Effect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus N. Engl. J. Med., March 26, 1998; 338(13): 861 - 866. [Abstract] [Full Text] [PDF]

				M. P. Stern The Effect of Glycemic Control on the Incidence of Macrovascular Complications of Type 2 Diabetes Arch Fam Med, March 1, 1998; 7(2): 155 - 162. [Abstract] [Full Text] [PDF]

				K. L. Jones Non-Insulin Dependent Diabetes in Children and Adolescents: The Therapeutic Challenge Clinical Pediatrics, February 1, 1998; 37(2): 103 - 110. [Abstract] [PDF]

				B. Gaster and I. B. Hirsch The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes Arch Intern Med, January 26, 1998; 158(2): 134 - 140. [Abstract] [Full Text] [PDF]

				J. E-B. Reusch Focus on Insulin Resistance in Type 2 Diabetes: Therapeutic Implications The Diabetes Educator, January 1, 1998; 24(2): 188 - 193. [PDF]

				H. R. Robert Glucose Control and Insulin Resistance in Non-Insulin-dependent Diabetes Mellitus Ann Intern Med, January 1, 1996; 124(1_Part_2): 97 - 103. [Abstract] [Full Text]